Catalyst Pharmaceutical Partners Receives Breakthrough Therapy Designation From FDA for Firdapse(TM) for the Treatment of LEMS

Catalyst Pharmaceutical Partners Receives Breakthrough Therapy Designation
From FDA for Firdapse(TM) for the Treatment of LEMS

CORAL GABLES, Fla., Aug. 27, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical
Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on
the development and commercialization of novel prescription drugs targeting
rare (orphan) neuromuscular and neurological diseases, today announced that
its investigational product Firdapse™ (amifampridine phosphate) has received
"Breakthrough Therapy Designation" by the U.S. Food and Drug Administration
(FDA) for the symptomatic treatment of patients with Lambert-Eaton Myasthenic
Syndrome (LEMS). Firdapse™ is Catalyst's investigational therapy that is being
evaluated for the treatment of the debilitating symptoms associated with LEMS,
including muscle weakness.

"We are very pleased to have received Breakthrough Therapy Designation for
Firdapse™ and we are excited by the FDA's decision to place our product in a
category that may enable expedited development and review for patients with
LEMS," said Patrick McEnany, President and Chief Executive Officer of
Catalyst. "With no approved or effective symptomatic treatment currently
available for LEMS, Firdapse™ has the potential to be the first-line treatment
option for patients with this rare condition."

Breakthrough Therapy Designation for Firdapse™ was based on clinical data from
several previously published clinical trials of amifampridine (3,4-DAP) in
patients with LEMS. Firdapse™ has the potential to provide significant relief
of the often debilitating symptoms of the disease, including muscle weakness
(e.g. difficulty walking), difficulty swallowing and talking, drooping of
eyelids and facial weakness.

About Breakthrough Therapy Designation

Breakthrough Therapy Designation was enacted as part of the 2012 Food and Drug
Administration Safety and Innovation Act (FDASIA). FDASIA defines breakthrough
therapy as a drug that is "intended, alone or in combination with one or more
other drugs, to treat a serious or life-threatening disease or condition and
preliminary clinical evidence indicates that the drug may demonstrate
substantial improvement over existing therapies on one or more clinically
significant endpoints, such as substantial treatment effects observed early in
clinical development."

A breakthrough therapy designation conveys all of the fast track program
features, as well as more intensive FDA guidance on an efficient drug
development program. The FDA also has an organizational commitment to involve
senior management in such guidance. The Breakthrough Therapy Designation is a
distinct status from both accelerated approval and priority review, which can
also be granted to the same drug if relevant criteria are met.

About Firdapse™

Firdapse™, also known as amifampridine phosphate, 3,4-diaminopyridine
phosphate or 3,4-DAP phosphate, is a potassium channel blocker. It delays
repolarization of the pre-synaptic neuron, causing voltage gated Ca2+ channels
to remain open longer. The increase Ca2+ influx causes more acetylcholine to
be released, making it more likely that a muscle action potential will be
initiated, thereby reducing muscle weakness. The North American rights to
Firdapse™ were licensed to the Company in 2012 by BioMarin Pharmaceutical.
BioMarin currently markets Firdapse™ in the EU for the treatment of LEMS.

In the United States, where the product has previously received orphan drug
designation, Firdapse™ is in a Phase III, multicenter, double-blind,
placebo-controlled, randomized discontinuation study followed by an open-label
extension period to evaluate the efficacy and safety of Firdapse™ in patients
with LEMS. In addition to LEMS, other potential orphan neuromuscular
indications for Firdapse™ include Myasthenia Gravis and Congenital Myasthenic
Syndrome, among others.

About LEMS

Lambert-Eaton Myasthenic Syndrome, LEMS, is a rare autoimmune disease that can
be severely disabling, with the primary symptom of muscle weakness. The
weakness is generally more marked in the proximal muscles, particularly of the
legs and trunk. Other problems include reduced reflexes, drooping of the
eyelids, facial weakness and problems with swallowing. Patients often report
dry mouth, impotence, constipation and feelings of light headedness on
standing. These problems can be life threatening when the weakness involves
respiratory muscles. The muscle weakness in LEMS is caused by autoantibodies
to voltage gated calcium channels, which cause a reduction in the amount of
acetylcholine released from nerve terminals. The prevalence of LEMS is
estimated at approximately 3,000 patients in the United States and Canada.
Approximately 50 percent of LEMS patients diagnosed have small cell lung
cancer. Patients with LEMS typically present with fatigue, muscle pain and
stiffness. A diagnosis of LEMS is generally made on the basis of clinical
symptoms, electromyographic and compound muscle action potential (CMAP)
testing and where available, the presence of autoantibodies against voltage
gated calcium channel.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of novel prescription drugs
targeting rare (orphan) neuromuscular and neurological diseases, including
Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette
Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, is
currently undergoing testing in a global, multi-center, pivotal phase III
trial. Catalyst is also developing a potentially safer and more potent
vigabatrin analog (designated CPP-115) to treat infantile spasms, and
epilepsy, as well as other neurological conditions associated with reduced
GABAergic signaling, like post-traumatic stress disorder and Tourette

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which may cause
Catalyst's actual results in future periods to differ materially from
forecasted results. A number of factors, including the timing of completion of
Catalyst's currently ongoing Phase III trial of Firdapse™, whether the Phase
III trial will be successful, whether the receipt of breakthrough therapy
designation for Firdapse™ will expedite the development and review of
Firdapse™ by the FDA or the likelihood that the product will be found to be
safe and effective, whether an NDA for Firdapse™ will ever be accepted for
filing by the FDA, the timing of any such NDA filing or acceptance, whether
any of Catalyst's product candidates will ever be approved for
commercialization or successfully commercialized, and those other factors
described in Catalyst's Annual Report on Form 10-K for the fiscal year 2012
and other filings with the U.S. Securities and Exchange Commission (SEC),
could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are
available from the SEC, may be found on Catalyst's website or may be obtained
upon request from Catalyst. Catalyst does not undertake any obligation to
update the information contained herein, which speaks only as of this date.

CONTACT: For Further Information Contact:
         Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         Melody Carey
         Rx Communications Group
         (917) 322-2571
Press spacebar to pause and continue. Press esc to stop.